Hanks, Brent A.
Duke University · Duke Cancer Institute
3 papers on CoChatORCID 0000-0002-2803-3272
Most cited papers
- Verified
Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., et al. (2019) · Journal of Clinical Oncology
Polyomavirus and related diseasesNonmelanoma Skin Cancer Studies
Cited by 396
- Verified
A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression
Plebanek, M. P., Xue, Y., Nguyen, Y.-V., DeVito, N. C., Wang, X., Holtzhausen, A., Beasley, G. M., Theivanthiran, B., & Hanks, B. A. (2024) · Science Immunology
Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers
Cited by 164
- Verified
Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research
Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases
Cited by 117
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free